The Spleen in Sickle Cell Anemia and Sickle Cell Thalassemia
NCT ID: NCT00971698
Last Updated: 2011-08-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
50 participants
OBSERVATIONAL
2009-02-28
2010-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In comparison in Sickle cell thalassemia patients, hypersplenism is more frequent.
The purpose of this study is to compare the clinical and laboratory issues related to the spleen in two groups of Sickle cell patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical and Laboratory Assessment of Iron Overload in Sickle Cell Anemia and Sickle Cell Thalassemia
NCT00512564
Invasive Infections in Children With Hemoglobinopathies
NCT00456443
Iron Overload and Growth Velocity in Thalassemia and Sickle Cell Anemia
NCT00972231
Blood Transfusions in Thalassemia Patients, Complications and Adverse Effects
NCT00971880
Iron Overload Assesment in Sickle Cell Anemia and Sickle Cell Thalassemia
NCT00512226
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Two groups of patient will be compared, a group of Sickle cell patients (Homozygous) and a second group of patients with Sickle cell beta thalassemia.
In those patients that splenectomy was performed the incidence of infections will be recorded besides the indications for splenectomy and the incidence of thrombotic events or thrombocytosis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sickle Cell Patients
Patients with homozygous Sickle Cell Anemia
No interventions assigned to this group
Sickle Cell Thalassemia
Patients with Sickle Cell Thalassemia
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
1 Year
35 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HaEmek Medical Center, Israel
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Koren Ariel
Head of Pediatric Hematology Unit and Pediatric Dpt B
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pediatric Hematology Unit and Pediatric Dpt B - HaEmek Medical Center
Afula, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0135-08-EMC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.